As of Friday close, Ironwood Pharmaceuticals Inc.’s (NASDAQ:IRWD) stock was up $0.39, moving up 3.40 percent to $11.87. The average number of shares traded per day over the past five days has been 3,626,420 shares. 3 times new highs have been achieved over the past 5 days, with a $0.42 gain in that time frame. In the last twenty days, the average volume was 2,530,300, while in the previous 50 days, it was 3,715,558.
Since last month, IRWD stock retreated -0.25%. Shares of the company fell to $10.78 on 08/02/22, the lowest level in the past month. A 52-week high of $14.27 was reached on 03/30/22 after having rallying from a 52-week low of $10.13. Since the beginning of this year, IRWD’s stock price has risen by 1.80% or $0.21, and marked a new high 9 times. However, the stock has declined by -16.82% since its 52-week high.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
Ironwood Pharmaceuticals Inc. (IRWD) last reported insider trading activity 5 days ago on Aug 01. MCCOURT Thomas A, the Chief Executive Officer of the company, disposed of 23,229 shares for $11.35 on Aug 01. It resulted in a $263,649 divestment by the insider. MCCOURT Thomas A sold 19,959 shares at an average price of $11.58 on Jun 30. The insider now owns 778,922 shares following the transaction. On Jun 14, Director Kessler Marla L sold 7,610 shares at $11.65 apiece. The transaction was valued at $88,656.
Right now, Ironwood Pharmaceuticals Inc. (IRWD) has a P/E ratio of about 3.73. The stock’s beta is 1.09. Besides these, the trailing price-to-sales (P/S) ratio of 4.67, the price-to-book (PB) ratio of 3.62.
In the three months ended March 30, Ironwood Pharmaceuticals Inc.’s quick ratio stood at 4.80, while its current ratio was 4.80, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending March 30 was 0.76, and the total debt-to-equity ratio was 1.00. In the year ended March 30, operating margins totaled 57.90%. Based on annual data, IRWD earned $413.75 million in gross profit and brought in $413.75 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 52.80%. Return on equity (ROE) for the past 12 months was 95.20%.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. IRWD’s revenue fell -19.63% to $103.75 million during the quarter, while net income inched up to $97.53 million. While analysts expected Ironwood Pharmaceuticals Inc. to report $0.25 quarterly earnings, the actual figure was $0.21 per share, beating the consensus estimate by -16.00%. During the quarter, the company generated $56.02 million in EBITDA. The liabilities of Ironwood Pharmaceuticals Inc. were 442.81 million at the end of its most recent quarter ended March 30, and its total debt was $536.76 million. The value of shareholders’ equity is $153.23 million.
This quick technical analysis looks at Ironwood Pharmaceuticals Inc.’s (IRWD) price momentum. With a historical volatility rate of 57.17%, the RSI 9-day stood at 55.22% on 05 August.
With respect to its five-day moving average, the current Ironwood Pharmaceuticals Inc. price is up by +3.67% percent or $0.42. At present, IRWD shares trade -0.17% below its 20-day simple moving average and +1.98% percent above its 100-day simple moving average. However, the stock is currently trading approximately +7.23% above its SMA50 and -11.68% below its SMA200.
Stochastic coefficient K was 43.27% and Stochastic coefficient D was 25.43%, while ATR was 0.46. Given the Stochastic reading of 63.74% for the 14-day period, the RSI (14) reading has been calculated as 53.25%. As of today, the MACD Oscillator reading stands at -0.12, while the 14-day reading stands at -0.17.
Piper Sandler launched its rating on Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD) to an Overweight in a note to investors on April 22, 2022. Ironwood Pharmaceuticals Inc. (IRWD) has been rated Hold by analysts. According to 0 brokerage firms, IRWD is a sell, and 3 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Ironwood Pharmaceuticals Inc. stock as buy, with 1 recommending it as overweight.
With a median target price of $12.50, the current consensus forecast for the stock is $9.00 – $16.00. Based on these forecasts, analysts predict Ironwood Pharmaceuticals Inc. (IRWD) will achieve an average price target of $12.50.